Details of the Drug Reposition

General Information of This Drug (ID: DM3PBMR)

Drug Name
INTERCEPT   DM3PBMR
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Blood transfusion DISH3QF7 QB98 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Infectious disease DISEM33Q 1A00-CA43.1 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Cerus.
2 ClinicalTrials.gov (NCT02310412) A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma. U.S. National Institutes of Health.